Pharmacogenetic predictors of development of secondary to enalapril dry cough in hypertensive patients
Objectives Development of the secondary to ACEI cough leads to discontinuation of the drugs of this group. Assessing the safety of the ACEIs with further development of customized approaches for their administration is a major scientific and practical problem. The objective of this study was to assess the association of the genetic markers with the development of the adverse drug reaction in the form of secondary to enalapril dry cough in the patients with essential arterial hypertension. Methods Study involved 113 patients with the secondary to enalapril cough and 104 patients without development of the secondary to enalapril adverse drug reaction. Results The patients carriers of the genotype AA rs2306283 of gene SLCO1B1 had 2-fold higher odds of developing the dry cough than those with the genotypes AG and GG (ОR=2.01, 95%CI=1.10–3.66, р=0.023). Similarly, the patients heterozygous for rs8176746 of gene АВО had 2.3-fold higher odds of developing the ADR in the form of dry cough than the carriers of the genotypes GG and TT (ОR=2.30, 95%CI=1.24–4.29, р=0.008). Conclusions Statistically significant association between the development of the ADR in the form of secondary to enalapril dry cough and polymorphisms rs2306283 of gene SLCO1B1 and rs8176746 of gene ABO was revealed..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Drug metabolism and personalized therapy - 38(2023), 3 vom: 19. Mai, Seite 247-254 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sychev, Ivan V. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2023 Walter de Gruyter GmbH, Berlin/Boston |
|---|
| doi: |
10.1515/dmpt-2023-0008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
GRUY009206884 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | GRUY009206884 | ||
| 003 | DE-627 | ||
| 005 | 20231205155302.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230916s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/dmpt-2023-0008 |2 doi | |
| 035 | |a (DE-627)GRUY009206884 | ||
| 035 | |a (DE-B1597)dmpt-2023-0008-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Sychev, Ivan V. |e verfasserin |0 (orcid)0000-0003-0227-2651 |4 aut | |
| 245 | 1 | 0 | |a Pharmacogenetic predictors of development of secondary to enalapril dry cough in hypertensive patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 Walter de Gruyter GmbH, Berlin/Boston | ||
| 520 | |a Objectives Development of the secondary to ACEI cough leads to discontinuation of the drugs of this group. Assessing the safety of the ACEIs with further development of customized approaches for their administration is a major scientific and practical problem. The objective of this study was to assess the association of the genetic markers with the development of the adverse drug reaction in the form of secondary to enalapril dry cough in the patients with essential arterial hypertension. Methods Study involved 113 patients with the secondary to enalapril cough and 104 patients without development of the secondary to enalapril adverse drug reaction. Results The patients carriers of the genotype AA rs2306283 of gene SLCO1B1 had 2-fold higher odds of developing the dry cough than those with the genotypes AG and GG (ОR=2.01, 95%CI=1.10–3.66, р=0.023). Similarly, the patients heterozygous for rs8176746 of gene АВО had 2.3-fold higher odds of developing the ADR in the form of dry cough than the carriers of the genotypes GG and TT (ОR=2.30, 95%CI=1.24–4.29, р=0.008). Conclusions Statistically significant association between the development of the ADR in the form of secondary to enalapril dry cough and polymorphisms rs2306283 of gene SLCO1B1 and rs8176746 of gene ABO was revealed. | ||
| 700 | 1 | |a Denisenko, Natalia P. |0 (orcid)0000-0003-3278-5941 |4 aut | |
| 700 | 1 | |a Kachanova, Anastasiya A. |0 (orcid)0000-0003-3194-4410 |4 aut | |
| 700 | 1 | |a Lapshtaeva, Anna V. |0 (orcid)0000-0003-4828-2476 |4 aut | |
| 700 | 1 | |a Goncharova, Ludmila N. |0 (orcid)0000-0002-4324-9071 |4 aut | |
| 700 | 1 | |a Mirzaev, Karin B. |0 (orcid)0000-0002-9307-4994 |4 aut | |
| 700 | 1 | |a Sychev, Dmitry A. |0 (orcid)0000-0002-4496-3680 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug metabolism and personalized therapy |d De Gruyter, 2015 |g 38(2023), 3 vom: 19. Mai, Seite 247-254 |h Online-Ressource |w (DE-627)GRUY00052929X |w (DE-600)2822040-7 |w (DE-576)433099526 |x 2363-8915 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2023 |g number:3 |g day:19 |g month:05 |g pages:247-254 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1515/dmpt-2023-0008 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_GRUY | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |j Pharmazie |j Pharmazeutika |q VZ |
| 951 | |a AR | ||
| 952 | |d 38 |j 2023 |e 3 |b 19 |c 05 |h 247-254 | ||